Skip to Content
Biotechnology

Drug giant invests $300 million in 23andMe and the promise of genetics

The pharma company GlaxoSmithKline will team with 23andMe on developing new drugs, it said in a statement.

What: The $300 million investment in 23andMe shows how drug companies are betting on human genetics to decide what medicines to pursue. Hal Barron, Glaxo’s R&D boss, said the deal was part of an effort to speed up the drug search. 

The database: It’s huge and getting bigger. 23andMe has DNA data on more than five million people, which it collected by selling them ancestry and health tests.

The business model: 23andMe has been looking to parlay its gene bank into drugs for a while now. It has other partners, like Pfizer, but this investment is the largest so far.

Richard Scheller, head of 23andMe’s drug team, described his company’s efforts as “nascent.” It does not yet have a drug in human testing, for example.

Treating brains: The companies said one of their first projects would be to develop a drug for Parkinson’s disease.

Deep Dive

Biotechnology

Sam Altman invested $180 million into a company trying to delay death

Can anti-aging breakthroughs add 10 healthy years to the human life span? The CEO of OpenAI is paying to find out.

Forget designer babies. Here’s how CRISPR is really changing lives

The gene-editing tool is being tested in people, and the first treatment could be approved this year.

Neuroscientists listened in on people’s brains for a week. They found order and chaos.

The study shows that our brains exist between chaos and stability—a finding that could be used to help tweak them either way.

More than 200 people have been treated with experimental CRISPR therapies

But at a global genome-editing summit, exciting trial results were tempered by safety and ethical concerns.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.